intralesional

Type: Keyphrase
Name: intralesional
First reported 12 hours ago - Updated 7 hours ago - 1 reports

Durable T-VEC Responses Fail to Prolong Survival in Updated Analysis

Michael A. Postow, MDTalimogene laherparepvec (T-VEC) significantly improved durable response rates (DRR) but failed to extend overall survival (OS) in patients with advanced melanoma, according to results from an analysis of the phase III OPTiM study ... [Published OncLive - 12 hours ago]
First reported Apr 17 2014 - Updated Apr 17 2014 - 1 reports

PV-10 decreases melanoma cells in tumours

by ecancer reporter Janet FrickerPV-10, an investigational drug, has demonstrated a reduction of viable melanoma cells in both injected tumours and non-injected bystander tumours, reported a study at the American Association for Cancer Research Annual ... [Published Ecancer Medicalscience - Apr 17 2014]
First reported Apr 16 2014 - Updated Apr 16 2014 - 1 reports

Prognostic Effect of Erroneous Surgical Procedures in Patients with Osteosarcoma Evaluation Using Propensity Score Matching

Background:Little is known concerning erroneous surgical procedures of malignant bone tumors, and the prognostic effect of erroneous surgical procedures in osteosarcoma has not been determined.Methods:We retrospectively reviewed 240 patients with initially ... [Published Journal of Bone and Joint Surgery - Apr 16 2014]
First reported Apr 15 2014 - Updated Apr 15 2014 - 1 reports

Intralesional collagenase in the treatment of Peyronie's disease - Abstract

The objective of intralesional pharmacotherapy in the treatment of Peyronie's disease is to deliver large doses of pharmacologic agents that can have a local effect on wound remodeling, with minimal side effects.Guidelines for the treatment of peyronie's ... [Published UroToday - Apr 15 2014]
First reported Apr 12 2014 - Updated Apr 13 2014 - 2 reports

Debate: Intralesional systemic therapy useful in unresected, regionally metastatic melanoma for local, regional control

NEW YORK –  Merrick I. Ross, MD, discusses his academic debate with Jeffrey S. Weber, MD, PhD , regarding the current role of systemic intralesional therapies.Ross illustrates that patients with unresectable, multiple, or advanced locally and regionally ... [Published Orthopedics Today - Apr 13 2014]
First reported Apr 09 2014 - Updated Apr 09 2014 - 1 reports

Peyronie's Disease: New Findings on Peyronie's Disease from G. Richards and Co-Authors Summarized

Today's Medical & Research NewsPeyronie's Disease2014 APR 09 -- By a News Reporter-Staff News Editor at Health & Medicine Week -- Fresh data on Peyronie's disease are presented in a new report. According to news reporting originating in New Hyde Park, ... [Published NewsRX - Apr 09 2014]
First reported Apr 08 2014 - Updated Apr 09 2014 - 1 reports

Viralytics Ltd announces positive interim phase 2 trial results for CAVATAK

Viralytics Ltd:Presented additional positive interim results from the ongoing Phase 2 CALM clinical trial.Reductions in non-injected tumours are a key measure of success for intralesional therapies such as CAVATAK, as it suggests generation of an anti-cancer ... [Published Reuters - Apr 08 2014]
First reported Apr 07 2014 - Updated Apr 07 2014 - 1 reports

Novel Treatment Strategy in Melanoma Misses End Point

A novel treatment approach for melanoma, which involves injecting a virus directly into the lesions of patients with advanced disease, does not significantly improve overall survival.The final clinical trial results for this melanoma "vaccine," talimogene ... [Published American Journal of Public Health - Apr 07 2014]
First reported Apr 03 2014 - Updated Apr 03 2014 - 1 reports

OncoSec Medical to Present at 2 Conferences in New York City in April

OncoSec Medical Inc., a company developing its ImmunoPulse DNA-based immunotherapy to treat solid tumors, will present at the 13th Annual Needham Healthcare Conference and the HemOnc Today Melanoma and Cutaneous Malignancies Meeting in April. According ... [Published Individual.com - Apr 03 2014]
First reported Apr 02 2014 - Updated Apr 02 2014 - 1 reports

Provectus Biopharmaceuticals’ PV-10 Data to Feature in Poster Presentation by Moffitt Cancer Center at …

KNOXVILLE, Tenn.--(BUSINESS WIRE)--Provectus Biopharmaceuticals, Inc. ( PVCT ) ( http://www.pvct.com ), a development-stage oncology and dermatology biopharmaceutical company, announced today that data on its investigational drug PV-10 will be featured ... [Published Yahoo! Finance - Apr 02 2014]
First reported Mar 28 2014 - Updated Mar 28 2014 - 1 reports

T-VEC Vaccine Promotes Tumor Shrinkage in Advanced Melanoma

The experimental cancer vaccine talimogene laherparepvec (T-VEC) promoted tumor shrinkage and triggered a systemic immune response in patients with advanced melanoma, according to the results of a study presented at the 2014 Society of Surgical Oncology ... [Published CancerConnect.com - Mar 28 2014]
First reported Mar 21 2014 - Updated Mar 21 2014 - 2 reports

Ascend Biopharmaceutical’s ASN-002 demonstrates favourable response in a Phase 2 study in Cutaneous B-Cell Lymphoma

Details Category: Vaccines Published on Friday, 21 March 2014 20:33 Hits: 3 Highlights In Cutaneous B-Cell Lymphoma • TG1042 (ASN-002) treatment is well tolerated with a high response rate • TG1042 treatment results in a durable response beyond treatment ... [Published PipelineReview - Mar 21 2014]

Quotes

...According to news reporting originating in New Hyde Park, New York, by NewsRx journalists, research stated, "Sonoelastography is an emerging ultrasound-based technique that allows characterization of tissue stiffness. The aim of this report is to present a case of significant penile curvature with a non-palpable, non-sonographically visualized plaque that was demonstrable with sonoelastography."
...in patients with metastatic melanoma," said Sean E Harper, MD, executive vice president of research and development at Amgen, in a statement. "We missed statistical significance on the secondary end point of overall survival, but the strong trend in survival benefit supports further research of talimogene laherparepvec to better understand its role in melanoma, both as a single agent and in combination with other therapies."
The poster, based upon abstract #9028, is entitled "Assessment of immune and clinical efficacy after intralesional PV-10 in injected and uninjected metastatic melanoma lesions" and is authored by Amod Sarnaik, MD and colleagues of Moffitt
...professor at the University of Utah Huntsman Cancer Institute, and the OPTiM study author, said in a release issued during the ASCO meeting. "The results of this study are encouraging in a disease as devastating as metastatic melanoma."

More Content

All (21) | News (20) | Reports (0) | Blogs (1) | Audio/Video (0) | Fact Sheets (0) | Press Releases (0)
sort by: Date | Relevance
Durable T-VEC Responses Fail to Prolong Surviva... [Published OncLive - 12 hours ago]
PV-10 decreases melanoma cells in tumours [Published Ecancer Medicalscience - Apr 17 2014]
Prognostic Effect of Erroneous Surgical Procedu... [Published Journal of Bone and Joint Surgery - Apr 16 2014]
Intralesional collagenase in the treatment of P... [Published UroToday - Apr 15 2014]
Debate: Intralesional systemic therapy useful i... [Published Orthopedics Today - Apr 13 2014]
Debate: Intralesional systemic therapy alone se... [Published Orthopedics Today - Apr 12 2014]
Peyronie's Disease: New Findings on Peyronie's ... [Published NewsRX - Apr 09 2014]
Viralytics Ltd Release: Positive Interim Phase ... [Published BioSpace - Apr 09 2014]
Viralytics' Cavatak shows immunotherapy potential [Published Australian Life Scientist - Apr 08 2014]
Viralytics Ltd announces positive interim phase... [Published Reuters - Apr 08 2014]
Novel Treatment Strategy in Melanoma Misses End... [Published American Journal of Public Health - Apr 07 2014]
OncoSec Medical to Present at 2 Conferences in ... [Published Individual.com - Apr 03 2014]
Provectus Biopharmaceuticals’ PV-10 Data to Fea... [Published Yahoo! Finance - Apr 02 2014]
Deploying the Body's Army [Published The Scientist - Apr 01 2014]
T-VEC Vaccine Promotes Tumor Shrinkage in Advan... [Published CancerConnect.com - Mar 28 2014]
Ascend Biopharmaceutical’s ASN-002 demonstrates... [Published PipelineReview - Mar 21 2014]
Ascend Biopharmaceuticals reports favourable re... [Published News-Medical.Net - Mar 21 2014]
Treatment of hepatitis C virus with telaprevir ... [Published PharmCast - Mar 19 2014]
9 Surprising Reasons Your Hair is Falling Out [Published Yahoo! Malaysia - Mar 18 2014]
T-VEC Promotes Tumor Shrinkage in Unresectable ... [Published OncLive - Mar 18 2014]
Cerebrospinal fluid pleocytosis in multiple scl... [Published Multiple Sclerosis Journal RSS feed -- OnlineFi ... - Dec 09 2013]
1
In Focus
  •  
  •  
  •  
  •  
  •  
  •  
  •  
  •  
  •  
Content Volume
Document Volume
Network
Network

Blogs

sort by: Date | Relevance
Cerebrospinal fluid pleocytosis in multiple scl... [Published Multiple Sclerosis Journal RSS feed -- OnlineFi ... - Dec 09 2013]
In multiple sclerosis (MS) occasionally acute lesions show a reduced apparent diffusion coefficient (ADC) on magnetic resonance imaging (MRI); however, the underlying mechanism of this phenomenon is not known. We compared cerebrospinal fluid (CSF) findings ...
1
Contact Us
Sales
Support


Freebase CC-BY Some image thumbnails are sourced from Freebase, licensed under CC-BY

Copyright (C) 2014 Silobreaker Ltd. All rights reserved.
The selection and placement of stories and images on any Silobreaker page are determined automatically by a computer program.
The time or date displayed reflects when an article was added to or updated in Silobreaker.